STOP THE WAR! Let’s support Ukraine Together

Iris Acquisition Corp (IRAA) to Combine with Liminatus Pharma in $334M Deal

Iris Acquisition Corp (IRAA) to Combine with Liminatus Pharma in $334M Deal

Iris Acquisition Corp. (NASDAQ:IRAA) has entered into a definitive agreement to combine with biotech firm Liminatus at an enterprise value of $334 million. La Palma, California-based Liminatus is a clinical-stage drug developer working on a range of cancer treatments utilizing both preventative vaccines and CAR-T therapies. The combined company is expected to trade on the
Read More

To access this post, you must purchase a Monthly or Yearly SPACInsider Subscription, or log in if you're a member.